EatDrama
Lifestyle

STAT Plus: Inhibrx claims first win for long-sought immunotherapy target

STAT Plus: Inhibrx claims first win for long-sought immunotherapy target

Inhibrx’s antibody INBRX-106 showed success in HPV-positive head and neck cancers.

Open original source

Article discussion

Comments stay attached to this story.

No comments yet.

Write a drama, celeb, gossip, or lifestyle post

Start a connected post from this article without changing the original story.

Featured Creators

Creators building their communities through the SpiderTaz Creator Program.

View creators →